A once-weekly shot of the compounded version of the active ingredient in Mounjaro and Zepbound
Compounded tirzepatide is the same version of the active ingredient in Mounjaro and Zepbound, used alongside diet and exercise to help people lose weight. It acts on two receptors instead of one, which is why patients in trials lost more weight on tirzepatide than on semaglutide. Compounded medications aren't FDA-approved but often come at significantly reduced costs. A Regenics provider will help you decide if it's right for you.
How you take it
A once-weekly injection you give yourself, starting at a low dose and stepping up over your first 4 months as your body adjusts.
Multiple hunger pathways
Tirzepatide acts on two receptors instead of one: GLP-1 and GIP, the gut hormones that tell your brain you're full and slow how fast your stomach empties.
What the trials showed
In the 72-week SURMOUNT-1 trial, participants without diabetes lost an average of 20.9% of their body weight, depending on dose. The greatest loss was at 15mg, paired with diet and exercise.
What it doesn't replace
This isn't about willpower. Weight regulation is biology, and the medication does the biological work your body needs help with.
Based on average body weight loss in tirzepatide trials. Your provider sets your dose, and your results depend on how you respond and the habits you build.
Starting weight: 260 lbs
You could lose:
52 pounds
Compounded tirzepatide is a once-weekly injection. It's a compounded version of the active ingredient in Mounjaro and Zepbound, prepared by a licensed US compounding pharmacy and prescribed by a Regenics provider. It acts on two receptors instead of one, GLP-1 and GIP, which is why patients in trials lost more weight on tirzepatide than on semaglutide.
Medication name: Compounded tirzepatide
Active ingredient: Tirzepatide
Drug type: GLP-1 + GIP receptor agonist
How it's taken: A once-weekly subcutaneous injection
Your tirzepatide weight loss treatment is prescribed and monitored by a licensed Regenics provider. They decide whether tirzepatide is right for you, set your starting dose, and adjust it as you respond. Care is month-to-month. You message your provider anytime, and dose changes don't trigger a visit fee.
Your provider decides whether you qualify. Not an automated approval
Care is built around long-term weight management, not one-time prescribing
Your dose starts low and steps up based on how you respond and how you tolerate it
Tarzana clinic and telehealth both available
Follow-up appointments track side effects and how you're responding
Your care is managed by the same licensed Regenics providers throughout your treatment. Unlike platforms where patients may see a different provider each time, Regenics is designed to provide continuity of care. They get to know your health history, monitor your progress, adjust your treatment when needed, and provide personalized care every step of the way.
Philip Marks, MSN, FNP-C
Philip is a board-certified family nurse practitioner with more than 14 years of clinical experience. He earned his MSN from UCLA and a Post-Master's FNP-C from UC Irvine. At Regenics, he specializes in hormone optimization, weight management, and peptide and regenerative therapies.
Paula Barash, FNP-C
Paula Barash, is a board-certified family nurse practitioner with over 6 years of nursing experience. She earned her Master of Science in Nursing from West Coast University, with a clinical background in perioperative and surgical care. At Regenics, she focuses on weight management, hormone optimization, and medical aesthetics.
Joanna Stuppler, MSN, NP-C
Joanna Stuppler, is a board-certified nurse practitioner with over 10 years of clinical experience spanning critical care, transplant surgery, internal medicine, and weight loss. She earned her Master of Science in Nursing from the University of Texas at Arlington. At Regenics, she focuses on weight management and preventive care.
Anna Gryunshpan, FNP
Anna is a family nurse practitioner with over 9 years of experience in aesthetic medicine. At Regenics, she specializes in injectables, skin rejuvenation, body contouring, weight management, hormone optimization, and peptide therapy. She also serves as a nurse educator to RNs, NPs, and PAs.
Online consultation for tirzepatide
Start with a short health questionnaire. A licensed Regenics provider reviews your answers and decides whether tirzepatide is right for you, checking BMI, weight-related conditions, treatment history, and safety.
A provider reviews and prescribes
If you qualify, your Regenics provider builds a care plan with a starting dose and a schedule for stepping it up. The plan covers when you inject and when your dose increases. Your provider adjusts the dose based on how you respond and how you tolerate it.
Ongoing monitoring and follow-up support
Care continues month-to-month. Follow-up appointments let your provider review side effects and adjust your dose when needed. If your provider recommends anything beyond your monthly plan, you'll see the timing and any fees before you decide.
Tirzepatide acts on two receptors, GLP-1 and GIP, that regulate appetite and how full you feel after meals. It also slows how fast your stomach empties. Your dose starts low and steps up gradually so your body can adapt, and your provider sets the schedule based on how you respond.
Most patients feel some nausea or constipation in the first few weeks. It usually fades. If it doesn't, you message your Regenics provider, and they can hold your dose, adjust it, or prescribe something for the nausea.
If Zepbound isn't the right fit, your Regenics provider can discuss other GLP-1 weight loss medications, including compounded semaglutide or brand-name, FDA approved Wegovy. What your provider recommends is based on your medical history and your goals.
Compounded · once-weekly injection
A good starting point if your provider wants to begin conservative or you're sensitive to GI side effects
Brand-name · FDA-approved
Costs more than the compounded options, with FDA approval tied to that exact formulation
These are individual patient experiences, not typical results. Individual results vary.
¹ Clinical trial data: In the 72-week SURMOUNT-1 study, participants receiving tirzepatide in combination with diet and exercise achieved mean weight reductions ranging from approximately 16% to 22.5%, depending on dose, with the highest reductions observed at 15 mg. Individual results vary.
² Long-term outcomes: In a 176-week clinical trial in adults with prediabetes and overweight or obesity, tirzepatide treatment was associated with a 94% relative reduction in progression to type 2 diabetes compared with placebo. Relative risk reduction differs from absolute risk reduction. Individual results vary.
³ Pricing shown reflects the prescription-only monthly subscription. Medication cost is separate and paid through the pharmacy. Pricing may vary by clinical eligibility.
